Lv7
4240 积分 2022-06-29 加入
Claudin 18.2 and Other Therapeutic Biomarkers in Gastric and Gastroesophageal Junction Adenocarcinomas
1个月前
已完结
Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial
2个月前
已关闭
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
2个月前
已完结
Cancer burden and control in China: landscape, trends and challenges
2个月前
已完结
Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries
2个月前
已完结
CLDN18.2-Targeted Therapy in Gastrointestinal Cancers
2个月前
已完结
Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)
2个月前
已完结
Accelerating drug development at Bristol Myers Squibb through innovation
4个月前
已完结
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
4个月前
已完结
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
4个月前
已完结
皖公网安备34019202002308
